TRI Supports AIDS Walk Washington

October 27, 2012 - Press Release

TRI raises awareness and funding for the Whitman Walker Health full-service community health center through participation in the annual AIDS Walk Washington that kicks off at Freedom Plaza in Washington, D.C.

TRI Introduces Thai Delegation Senior Officials to U.S. Best Practices for Refurbished Medical Equipment.

September 8, 2012 - Press Release

TRI encourages its employees to engage in socially responsible activities and events that are designed to support the community. Working with organizations that strengthen the community and work to better lives is a win-win for both the community and TRI. The benefits of acting socially responsible are plentiful, in that not only does it raise awareness and funding for an organization, issue, or disease, but it also strengthens the local economy and builds camaraderie.

Technical Resources International, Inc. (TRI) is proud to have provided regulatory, safety, and technical support to the Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), NIH for the HIV clinical trial that was chosen as the 2011 Breakthrough of the Year by Science Magazine.

May 18, 2012 - Press Release

The NIAID-sponsored HPTN 052 study was an international HIV prevention trial conducted in nine countries. Investigators conducting the study reported that HIV-infected heterosexual individuals who began taking antiretroviral medicines when their immune systems were relatively healthy were 96 percent less likely to transmit the virus to their uninfected partners.

Technical Resources International, Inc. (TRI) is proud to have contributed regulatory and technical support to the Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), NIH for the HIV study titled “Chemoprophylaxis for HIV Prevention in Men.”

May 18, 2012 - Press Release

Results of this trial, published in the New England Journal of Medicine in 2010, indicated that a daily dose of an oral antiretroviral drug (Gilead’s Truvada®), currently approved to treat HIV infection, reduced the risk of acquiring HIV infection by 43.8 percent among men who have sex with men. Participants who adhered most closely to the daily drug regimen had the highest rates of effectiveness of up to 72.8 percent.

TRI Debuts New Booth at Partnerships in Clinical Trials 2012

March 5-7, 2012